|会社名||Quest Diagnostics Inc. （DGX クエスト・ダイアグノスティックス）|
|業種||ヘルスケア施設_サ―ビス 医療関連（Health Care）|
|概要||事業概要 クエスト・ダイアグノスティクス(Quest Diagnostics Incorporated)は診断情報サービスのプロバイダである。同社は診断情報サービスと診断ソリューションという2つの事業を通じて事業を行う。診断情報サービス事業は患者、臨床医、病院、統合送達ネットワーク（IDN）、医療計画、雇用主、アカウンタブルケア組織（ACO）を含む顧客向けインサイトを提供する診断テスト情報とサービスを開発する 。診断ソリューション事業には保険会社向けのソリューションを提供するリスクアセスメントサービス事業と、医療提供者向けのソリューションを提供する医療情報技術ビジネスが含まれる。同社のサービスは「Quest Diagnostics」ブランドで提供され、「AmeriPath」、「Dermpath Diagnostics」、「Focus Diagnostics」、「Athena Diagnostics」、「ExamOne」、「Quanum」、「Care360」などの他のブランドのサービスも提供する。 クエスト・ダイアグノスティクスは米国の医療検査サ―ビス企業。医療診断検査や医療情報、関連サ―ビスを提供。血液・尿・微生物検査や生体組織・細胞検査、遺伝子検査、臨床試験を行うほか、診断検査キットを製造・販売する。検査結果閲覧システム「Care360」、カルテ管理システム「ChartMaxx」、その他医療関連ソフトウェアを提供。本社はニュ―ジャ―ジ―州。 Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.|
|代表者氏名||Stephen H. Rusckowski|
|代表者役職名||Chairman of the Board President Chief Executive Officer|
|決算概要||決算概要 BRIEF: For the fiscal year ended 31 December 2018 Quest Diagnostics Inc revenues increased 2% to $7.53B. Net income applicable to common stockholders excluding extraordinary items increased 8% to $719M. Revenues reflect DIS Business segment increase of 2% to $7.2B. Net income benefited from General corporate activities segment loss decrease of 10% to $181M. Dividend per share increased from $1.80 to $1.95.|
Nvidia stock falls after U.S. government restricts chip sales to China 2022/09/01 01:18:48 Kwhen Finance
Quest Diagnostics Incorporated – Consensus Indicates Potential 14.0% Upside 2022/08/30 13:00:20 DirectorsTalk
Quest Diagnostics Incorporated found using ticker (DGX) now have 14 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 160 and 129 and has a mean target at 144.86. With the stocks previous close at 127.1 this is indicating there is a potential upside of 14.0%. The 50 day MA is 135.35 and the 200 day MA is 141.05. The market capitalisation for the company is $14,766m. Company Website: https://www.questdiagnostics.com [stock_market_widget type="chart" template="basic" color="green" assets="DGX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $16,829m based on the market concensus. Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
3 Top Monkeypox Stocks to Buy Right Now 2022/08/24 15:40:04 InvestorPlace
With the latest outbreak now reported in all 50 states per ABC News , investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts. For one thing, the risks are real. According to the New England Journal of Medicine , monkeypox is a zoonotic orthopox DNA virus related to the virus that causes smallpox . While cases have circulated for decades, research has been neglected and underfunded. Not only does infection cause pain, it can also lead to organ injury. Therefore, the framework for the top monkeypox stocks to buy right now commands sober attention. Additionally, monkeypox symptoms create anxieties and distress. Therefore, significant incentives undergird these top monkeypox stocks to buy right now. DGX Quest Diagnostics $128.83 BVNRY Bavarian Nordic $16.15 EBS Emergent BioSolutions $27.28 Quest Diagnostics (DGX) Source: Sundry Photography / Shutterstock.com Arguably one of the more conservative names among the top monkeypox stocks to buy, Quest Diagnostics (NYSE: DGX ) offers clinical assessments.
Sharon Robins Joins Precipio''s Products Division as Senior Director of Laboratory & Hospital Sales 2022/08/24 15:00:00 Benzinga
NEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO ) , welcomes Sharon Robins as the Company''s Senior Director of Laboratory & Hospital Sales for the Product''s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (annualized run rate), Ms. Robins will be tasked with managing that relationship and ensuring its success. Coming from Qiagen, a market leader in the diagnostic reagents field, Ms. Robins brings with her a strong background in multiple leadership positions in diagnostic product sales. During her tenure at Qiagen she was responsible for over $100M in annual revenues. Sharon has a strong background in diagnostics distribution, previously holding senior sales positions at Quest Diagnostics, ThermoFisher, and Life Technologies. In those roles she led teams and was responsible for triple-digit million-dollar revenues. "We are extremely fortunate to have attracted an executive of Sharon''s caliber to our company.
Quest Diagnostics Incorporated – Consensus Indicates Potential 6.9% Upside 2022/08/23 11:18:48 DirectorsTalk
Quest Diagnostics Incorporated with ticker code (DGX) have now 14 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 160 and 129 with the average target price sitting at 144.86. Now with the previous closing price of 135.48 this is indicating there is a potential upside of 6.9%. The day 50 moving average is 135.34 and the 200 moving average now moves to 141.4. The company has a market capitalisation of $15,798m. Company Website: https://www.questdiagnostics.com [stock_market_widget type="chart" template="basic" color="green" assets="DGX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $16,892m based on the market concensus. Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
3 Monkeypox Stocks to Buy as Biden Declares Public Health Emergency 2022/08/05 17:27:44 InvestorPlace
The White House has declared monkeypox a public health emergency . Within the last two weeks, California, New York and Illinois making the same declaration already, and many other states are sounding the alarm. With the Joe Biden administration finally issuing this decree, though, public health officials have more flexibility to take action. The Washington Post reports that a second declaration is also under consideration. Under it, public health officials could “expedite medical countermeasures, such as potential treatments and vaccines, without going through full-fledged federal reviews.” Details are still emerging but one thing is clear; the U.S. is about to see a new focus on monkeypox vaccines. This means an influx in demand for the companies that produce them. Investors are already assessing the best monkeypox stocks. The Covid-19 pandemic isn’t over but the U.S. is already entering a new vaccine boom. But the delayed vaccine rollout continues to raise questions. CNN reports that the U.S. delayed a large-scale vaccine order out of fear of the shots expiring before being administered.
QUEST DIAGNOSTICS BRIDGING ACCESS TO BETTER HEALTH FOR HISPANICS THROUGH ES TU PODER INITIATIVE 2022/08/04 11:00:00 PR Newswire
IRVING, Texas, Aug. 4, 2022 /PRNewswire/ -- Better healthcare among America''s large and growing Hispanic community is receiving an important, new level of support from Quest Diagnostics, the world''s leading provider of diagnostic information services, through the launch of a multi-faceted…
Drug Testing At Work Is A Thing Of The Past, Study Finds 2022/07/30 16:39:11 Benzinga
According to a study conducted by Quest Diagnostics Inc (NYSE: DGX ), drug use among American employees, as measured by the percentage of employees who tested positive in urine drug tests, hit a 14-year high in 2018, reaching 4.4 percent. Cannabis continues to be the most popular substance, with 2.8 percent of all employees tested showing positive results. The news led addiction experts at the American Addiction Centers to wonder about the impact this might have on pre-employment drug testing in professionals. Seeking for an answer, they conducted an analysis of job postings on the popular website Glassdoor. They were trying to find out what types of jobs are most likely to include requirements for drug tests, and regular drug screening. Overall, remarkably few jobs disclose that they require drug testing before confirming employment, or during employment. On average, only 1.47 percent of job postings in the U.S. mention that they require pre-employment drug tests. See also:
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2022 Results - Earnings Call Transcript 2022/07/21 20:14:03 Seeking Alpha
Quest Diagnostics Incorporated (NYSE:NYSE:DGX) Q2 2022 Earnings Conference Call July 21, 2022 08:30 ET Company Participants Shawn Bevec - Vice President of Investor Relations Steve…
Quest Diagnostics PT Lowered to $142 at CFRA 2022/07/21 20:02:01 Investing.com
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi''s Pemphigus Trial Disappointment, Humanigen''s COVID-19 Drug Denied Emergency Use Authorization 2021/09/09 12:17:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE: ABT ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced its quarterly results) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) ICU Medical, Inc. (NASDAQ: ICUI ) (announced a deal to buy Smiths Medical division for $2.35 billion in cash) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Kadmon Holdings, Inc. (NASDAQ: KDMN ) - announced a deal to be bought by Sanofi (NASDAQ: SNY ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Medtronic plc (NYSE: MDT ) MiMedx Group, Inc. (NASDAQ: MDXG ) Nuvalent, Inc. (NASDAQ: NUVL ) (announced its second-quarter results) Quest Diagnostics Incorporated (NYSE: DGX ) ResMed Inc.
Quest Diagnostics raises 2021 guidance to reflect strong COVID-19 test volumes 2021/09/09 11:40:09 Seeking Alpha
Quest Diagnostics Raises 2021 Guidance 2021/09/09 11:22:00 FinanzNachrichten
WASHINGTON (dpa-AFX) - Quest Diagnostics Incorporated (DGX) has updated its financial outlook for full year 2021. The company said COVID-19 molecular testing volumes were stronger than expected th
Quest Diagnostics raises 2021 profit outlook on uptick in COVID-19 testing 2021/09/09 10:54:37 Financial Post
Quest Diagnostics Inc raised its full-year profit outlook on Thursday, saying it expects an uptick in COVID-19 testing demand due to the surge in infections from the Delta variant of the coronavirus. The U.S. lab now expects adjusted diluted earnings per share for 2021 to be in the range of $11.65 to $12.35 compared with 
IVD Market Size | Is Projected to Grow USD 153.67 Billion in 2028 at a CAGR of 6.9% 2021/09/09 10:49:00 Intrado Digital Media
Key Prominent Players Covered in the In vitro Diagnostic Market Research Report Are Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Sysmex Corporation, Siemens Healthineers AG, BD, Seegene Inc., DiaSorin S.p.A., Quest Diagnostics Incorporated Key Prominent Players Covered in the In vitro Diagnostic Market Research Report Are Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Sysmex Corporation, Siemens Healthineers AG, BD, Seegene Inc., DiaSorin S.p.A., Quest Diagnostics Incorporated
関連キーワード （ヘルスケア施設_サ―ビス 米国株 DGX クエスト・ダイアグノスティックス DGX ）